Stockscreener 앱 받기
0.15%
시간 외 거래:
Pfizer Inc 주식(PFE)의 최신 뉴스
Comirnaty and Pfizer's mRNA vaccine in the U.S. market - AD HOC NEWS
Is Pfizer Stock a "Value Trap" or a Generational Opportunity? - Yahoo Finance
Pfizer (PFE) Reports Promising Results from Breakwater Trial - GuruFocus
Pfizer (PFE) Unveils Promising Talzenna Study Results for Prosta - GuruFocus
Pfizer Inc. stock (US7170811035): TALZENNA plus XTANDI data and stakeholder moves keep focus on onco - AD HOC NEWS
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies - Yahoo Finance
Why Wall Street Is Dead Wrong About This Popular Stock - The Motley Fool
Pfizer says Talzenna plus Xtandi improves radiographic progression-free survival by over 50% in metastatic prostate cancer - marketscreener.com
Pfizer’s US$10.5b Oncology Deal With Innovent And What It Means For Valuation - simplywall.st
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing - MedCity News
Pfizer, HP among top 10 large-cap value stocks - MSN
Pfizer Inks Up to $10.5B Innovent Biotech Licensing Deal - Gotrade
Pfizer School of Science Mobile Experience Makes STEM Learning Fun - PIX11
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal - BioWorld News
Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market - TipRanks
Pfizer says EC authorizes update to pediatric use of Pfizer & BioNTech Covid 19 vaccine - marketscreener.com
Pfizer Inc. stock (US7170811035): Oncology deal with Innovent reshapes pipeline focus - AD HOC NEWS
Pfizer (PFE) Reveals Promising Seven-Year Findings from CROWN Tr - GuruFocus
Pfizer (PFE) Among Most Attractively Valued U.S. Stocks - GuruFocus
Pfizer, Innovent strike $10B cancer drug deal - BioPharma Dive
Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal - GuruFocus
Turning Silence Into Advocacy: Women Reshaping Cancer Conversations - Pfizer
Pfizer's Lorbrena Shows 55% Likelihood of Progression-Free Survival After Seven Years in NSCLC Study - marketscreener.com
Pfizer, Innovent Strike $10.5 Billion Oncology Deal to Develop 12 Cancer Medicines - Contract Pharma
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer - Business Wire
Pfizer and Innovent Biologics sign $10.5B cancer drug deal - Yahoo Finance
Pfizer partners with Innovent for $10.5bn to advance ADC oncology medicines - European Pharmaceutical Review
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal - Pharmaceutical Technology
Pfizer and China's Innovent sign major deal on cancer treatment - medwatch.com
Pfizer (PFE) Partners with Innovent Biologics in $10.5B Oncology Deal - GuruFocus
PFE Stock Quote Price and Forecast - CNN
Pfizer, Innovent Biologics Strike Cancer Drug Partnership Worth up to $10.5 Billion - marketscreener.com
Pfizer signs up to $10.5B oncology deal with China’s Innovent (PFE:NYSE) - Seeking Alpha
Innovent Biologics and Pfizer Joint Development of 12 Oncology ProgrammesNews and Statistics - IndexBox
Innovent Biologics, Pfizer strike $10.5 billion cancer drug deal amid China biotech boom - WKZO
Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics - BusinessLine
Innovent Biologics, Pfizer strike US$10.5 bil cancer drug deal amid China biotech boom - The Edge Malaysia
Pfizer Inks Up to $10.5 Billion Deal With China’s Innovent - Bloomberg.com
INNOVENT BIO Leaps ~8% on Strategic Collaboration with Pfizer Covering 12 Projects - AASTOCKS.com
INNOVENT BIO Forms Strategic Collaboration with Pfizer on 12 Projects with Total Deal Value of USD10.5B - AASTOCKS.com
Pfizer inks up to $10.5 billion deal With China’s Innovent - Moneycontrol.com
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines - The Manila Times
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal - Reuters
Should Pfizer’s (PFE) New 25‑Valent Vaccine Data and Oncology Alliance Require Action From Investors? - simplywall.st
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines - Business Wire
Pfizer, Innovent Sign Licensing Deal to Develop 12 Cancer Drugs - marketscreener.com
Wardlaw+Hartridge Student Receives Pfizer Scholarship - TAPinto
Pfizer’s New Phase 1 Trial Signals Steady Early-Stage Pipeline Progress - TipRanks
For this Pfizer Scientist, Cancer Research is Personal - Pfizer
Insiders Aren’t Buying Pfizer Stock at $26 and That’s Actually a Good Thing - 24/7 Wall St.
Pfizer Inc. stock (US7170811035): webcast announcement and recent earnings keep focus on US pharma h - AD HOC NEWS
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28 - Moomoo
Barclays Maintains Pfizer(PFE.US) With Sell Rating, Maintains Target Price $25 - Moomoo
PFIZER INC : Barclays reiterates its Sell rating - marketscreener.com
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferenceMay 27, 2026 - BioSpace
Pfizer Options Spot-On: On May 27th, 93,750 Contracts Were Traded, With 2.56 Million Open Interest - Moomoo
Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial - TipRanks
Pfizer to Webcast Healthcare Conference Discussion - geneonline.com
UBS maintains Pfizer stock rating ahead of cancer drug trial results - Investing.com
Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure? - Yahoo Finance
BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results - Insider Monkey
Pfizer (PFE.US) has received approval in China for a new formulation of its blockbuster anti-infective innovative drug, further enhancing the treatment regimen for invasive fungal diseases in children. - Moomoo
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $27 - Moomoo
1.31%
0.09%
자본화:
|
볼륨(24시간):